SynthesisBMC infectious diseases2023
Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT, T-SPOT.TB and TST: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- How to diagnose TB in migrants? A systematic review of reviews and decision tree analytical modelling exercise to evaluate properties for single and combined tuberculosis screening tests.The European respiratory journal · 2025Pooled it
- Evaluating the Cepheid Xpert TB/LTBI Research-Use-Only Assay for Detection of Active and Latent Mycobacterium tuberculosis Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Infectious Spondylodiscitis of Bacterial Causes in Adults: Epidemiology, Pathophysiology, Diagnostic and Treatment Challenges.Microorganisms · 2026Review
- Demographic and clinical correlates of discordant QuantiFERON TB Gold tuberculosis screening results in a low-incidence setting.Microbiology spectrum · 2026Article
- Article
- Giant Bilateral Iliopsoas Abscesses, Secondary to Pott's Disease: Challenging Diagnostic-Therapeutic Protocol Management (Modern and Innovative Open Approach Technique Through J.L. Petit Triangle)-A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study.The Lancet regional health. Europe · 2025Article
- Article
- Latent tuberculosis infection screening of adult close contacts: a cost-utility analysis.ERJ open research · 2025Article
- Effectiveness of tuberculosis preventive treatment in patients with rheumatic diseases: a global systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Comparison of Two Interferon-Gamma Release Assays for Pediatric Tuberculosis Infection.Journal of the Pediatric Infectious Diseases Society · 2025Observational
- Immunological testing and machine learning in detecting latent tuberculosis among high-risk groups (nature review).Frontiers in medicine · 2025Review
- The impact of IGRA positivity in untreated inactive pulmonary tuberculosis on IVF-ET outcomes in infertile women: an ambispective cohort study.Frontiers in medicine · 2025Article
- Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study.The Lancet. Global health · 2024Article
- Article
- Performance of the T-SPOT.TB test in patients with indeterminate QuantiFERON-TB Gold Plus results: proposal for an algorithm for the diagnosis of Latent Tuberculosis Infection.Le infezioni in medicina · 2024Article
- Prevalence of latent tuberculosis infection (LTBI) in healthcare workers in Latin America and the Caribbean: systematic review and meta-analysis.Le infezioni in medicina · 2024Review
- Accuracy of QuantiFERON in active tuberculosis suspects with comorbidities and nontuberculous mycobacterial infection in Northern California.Journal of clinical microbiology · 2023Article
- Latent tuberculosis infection (LTBI) in health-care workers: a cross-sectional study at a northern Peruvian hospital.Frontiers in medicine · 2023Article
- Latent Tuberculosis Infection among Household Contacts of Tuberculosis Patients, Healthcare Workers, and Tuberculosis Patients Using QuantiFERON-tuberculosis Gold Plus and Tuberculin Skin Test in a Tertiary Care Hospital Setting Bhubaneswar, Odisha - A Cross-sectional Study.Journal of global infectious diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundQuantiFERON-TB Gold Plus (QFT-Plus) is an important test that has emerged in recent years for detecting TB infection. We conducted a review to compare the sensitivity, specificity and positive rate of QFT-Plus with that of QuantiFERON-TB Gold In-Tube (QFT-GIT), T-cell spot of tuberculosis assay (T-SPOT.TB) and Tuberculin test (TST).
methodsPubMed and Embase were searched, without language restrictions, from 1 January 2015 to 31 March 2022 using "Mycobacterium tuberculosis Infections" and "QuantiFERON-TB-Plus" as search phrases. We estimated the sensitivity from studies of patients with active tuberculosis, specificity from studies of populations with very low risk of TB exposure, and positive rate from studies of high-risk populations. The methodological quality of the eligible studies was assessed, and a random-effects model meta-analysis was used to determine the risk difference (RD). We assessed the pooled rate by using a random-effects model. This study was registered in PROSPERO (CRD 42021267432).
resultsOf 3996 studies, 83 were eligible for full-text screening and 41 were included in the meta-analysis. In patients with active TB, the sensitivity of QFT-Plus was compared to that of QFT-GIT and T-SPOT.TB, respectively, and no statistically differences were found. In populations with a very low risk of TB exposure, the specificity of QFT-Plus was compared with that of QFT-GTI and T-SPOT.TB, respectively, and no statistically differences were found. Two studies were eligible to compare the specificity of the QFT-Plus test with that of the TST test, and the pooled RD was 0.12 (95% CI 0.02 to 0.22). In high-risk populations, 18 studies were eligible to compare the positive rate of the QFT-Plus test with that of the QFT-GIT test, and the pooled RD was 0.02 (95% CI 0.01 to 0.03). The positive rate of QFT-Plus was compared with that of T-SPOT.TB and TST groups, and no statistically differences were found.
conclusionsThe diagnostic performance of QFT-Plus was similar to that of QFT-GIT and T-SPOT.TB, but was slightly more specific than TST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.